Calamos Wealth Management LLC Sells 18,727 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Calamos Wealth Management LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 92.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,637 shares of the medical research company’s stock after selling 18,727 shares during the period. Calamos Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $852,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in TMO. Legacy Investment Solutions LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $26,000. Peterson Financial Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $27,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Endeavor Private Wealth Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at approximately $50,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on TMO shares. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday. Wells Fargo & Company boosted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Finally, Bernstein Bank lifted their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $658.00.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This represents a 38.12 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 29,000 shares of company stock worth $15,859,540. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.7 %

Shares of TMO stock opened at $593.38 on Tuesday. The company’s fifty day simple moving average is $541.37 and its two-hundred day simple moving average is $571.18. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock has a market cap of $226.97 billion, a P/E ratio of 35.90, a PEG ratio of 4.06 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts predict that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.44%.

Thermo Fisher Scientific declared that its board has initiated a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.